retatrutide type 2 diabetes phase 2 trial In the 3 TRANSCEND-T2D-1 trial, patients with experienced: ✓ Up to 2% A1C reduction ✓ 90% achieved an A1C <7% ✓ 85% achieved an A1C <6.5% ✓ 46% VisualAbstract: Retatrutide reduces body weight

With that caveat, here is what the published Phase 3 data say at peak dose, in adults with obesity and without diabetes: The roughly 6-percentage-point gap between retatrutide and tirzepatide at peak dose, sustained across more than 2,000 participants, is the data point payers and prescribers will spend the next year arguing about

Wang, C

Thus, the dynamics of GLP-1 needs to be carefully investigated in hyperthyroid mouse models in the future, which will help to understand the glucose metabolism in patients with clinical hyperthyroidism

Weight loss visible and steady

[DOI] [PMC free article] [PubMed] [Google Scholar] 33.Patel D., Smith A

The pre-specified primary efficacy analyses included data from study 1 and pooled data from studies 2 and 3, regardless of glycemic rescue or treatment discontinuation